Author

LA Garraway

Institutions: Novartis (Switzerland), Vanderbilt University, Dana-Farber Cancer Institute, Novartis Institutes for BioMedical Research

Observed institutions: Novartis (Switzerland), Vanderbilt University, Dana-Farber Cancer Institute, Novartis Institutes for BioMedical Research

OpenAlex ID: A5000715365

S3-4: ER Downregulation with Fulvestrant in Combination with pan-PI3K Inhibitor BKM120 Synergizes Against ER+/PI3K-Mutant Breast Cancer Xenografts In Vivo.

2011 · TW Miller, EM Fox, et al. · Cancer Research

Works count: 1

Citation count:

H-index:

I10-index: